ArticleArthritis research & therapy2010
FoxP3 and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development.
Article in Arthritis research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- NAC1 modulates autoimmunity by suppressing regulatory T cell-mediated tolerance.Science advances · 2022Article
- Cell-based therapies for rheumatoid arthritis: opportunities and challenges.Therapeutic advances in musculoskeletal disease · 2022Review
- Article
- Transiently Activated Human Regulatory T Cells Upregulate BCL-XL Expression and Acquire a Functional AdvantageFrontiers in immunology · 2019Article
- FOXP3 interacts with hnRNPF to modulate pre-mRNA alternative splicing.The Journal of biological chemistry · 2018Article
- miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg).Cell death & disease · 2018Article
- Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity.Journal of visualized experiments : JoVE · 2016Article
- Development of Auto Antigen-specific Regulatory T Cells for Diabetes Immunotherapy.Immune network · 2016Review
- Stem Cell-Derived Regulatory T Cells for Therapeutic Use in Arthritis.Autoimmune and infectious diseases : open access · 2016Article
- Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.Cell transplantation · 2016Article
- Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity.Oncotarget · 2015Review
- Manipulating regulatory T cells: a promising strategy to treat autoimmunity.Immunotherapy · 2015Review
- Modulation of autoimmune diseases by iPS cells.Methods in molecular biology (Clifton, N.J.) · 2014Article
- Utilizing regulatory T cells against rheumatoid arthritis.Frontiers in oncology · 2014Review
- Treg cells in rheumatoid arthritis: an update.Current rheumatology reports · 2013Review
- Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis.Arthritis · 2012Article
- Bcl-xL affects the development of functional CD4 Tregs.Arthritis research & therapy · 2010Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionForkhead box p3 (FoxP3)-expressing regulatory T cells (Tregs) have been clearly implicated in the control of autoimmune disease in murine models. In addition, ectopic expression of FoxP3 conveys a Treg phenotype to CD4(+) T cells, lending itself to therapeutic use in the prevention of rheumatoid arthritis (RA). In this study, we generated therapeutically active Tregs with an increased life span and hence greater therapeutic potential.
methodsWe used retrovirus-mediated transduction to introduce FoxP3 or FoxP3 with anti-apoptotic Bcl-2 family molecule Bcl-xL linked by a 2A picornavirus self-cleaving peptide into CD4(+) T cells to generate Tregs. In addition, by using in vitro functional analyses and adoptive immunotherapy in a murine model of RA, we demonstrated that these Tregs were highly reactive.
resultsWe found that CD4(+) T cells expressing both FoxP3 and Bcl-xL were able to differentiate into functional Tregs, which have a long-term survival advantage over cells transduced with FoxP3 alone. In an in vivo murine model, adoptive transfer of Tregs expressing both FoxP3 and Bcl-xL demonstrated more effective suppression of RA than CD4(+) T cells expressing FoxP3 alone.
conclusionsFoxP3 and Bcl-xL can cooperatively promote the differentiation and persistence of Tregs, with the capacity to prevent arthritis. Our results provide a novel approach for generating highly reactive Tregs for augmenting cellular immunotherapy for autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.